Earlier this week, Co-Diagnostics, Inc. (NASDAQ:CODX) (the Company), a molecular diagnostics company with a unique, patented diagnostics testing platform, announced that its partner, Clinical ...
Another billion-dollar-plus deal failed to play out as planned as the FDA dealt Teva Pharmaceutical Industries Ltd. a complete response letter (CRL) on its new drug application (NDA) for SD-809 ...
The saliva-based CRL Rapid Response Test is focused on getting businesses and schools back to work. Clinical Reference Laboratories CEO Robert Thompson joins Jill Malandrino on Nasdaq #TradeTalks to ...
Replimune Group, Inc. received a surprising FDA Complete Response Letter for RP1, citing inadequate trial design and concerns over data interpretation. RP1's delayed approval and the need for a new ...
Charles River International Laboratories, Inc. CRL recently launched Endosafe Trillium rCR cartridges, which combine its hallmark Endosafe cartridge technology with recombinant cascade reagent (rCR).
New York City, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Saliva-Based Test Powered by Co-Diagnostics (NASDAQ:CODX) a Game Changer Maxim reiterate Buy with a price target of $30 Earlier this week, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback